Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2018, Article ID 4292509, 8 pages
https://doi.org/10.1155/2018/4292509
Research Article

Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice

1Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea
2Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea

Correspondence should be addressed to Bon Jeong Ku; rk.ca.unc@gnoejnob

Received 10 October 2017; Revised 22 January 2018; Accepted 20 May 2018; Published 13 June 2018

Academic Editor: Ruth Roberts

Copyright © 2018 Sorim Choung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [2 citations]

The following is the list of published articles that have cited the current article.

  • Yu Seol Lee, Jeong Su Park, Da Hyun Lee, Dong-Kyu Lee, Sung Won Kwon, Byung-Wan Lee, and Soo Han Bae, “The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition,” Frontiers in Endocrinology, vol. 9, 2018. View at Publisher · View at Google Scholar
  • Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, and Cheol-Young Park, “Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment,” Diabetes & Metabolism Journal, vol. 43, no. 2, pp. 127, 2019. View at Publisher · View at Google Scholar